E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hypovolemia is the condition under investigation. Hypovolemia is induced by the "lower body negative pressure" (LBNP)-model.
|
|
E.1.1.1 | Medical condition in easily understood language |
The study investigates the response to volume loss, e.g. bleeding, in a model where blood is displaced to the legs and lower abdomen. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physiological processes [G07] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10049771 |
E.1.2 | Term | Shock haemorrhagic |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Supplemental oxygen is frequently administered in acutely and critically ill patients, specifically, it is often administered in trauma patients to avoid arterial hypoxemia and tissue hypoxia. There is also an increasing focus on potentially deleterious effects of hyperoxia. Further, the hemodynamic response to hyperoxia in hypovolemia is poorly understood. The present study aims to investigate the effects of supplemental oxygen on systemic and cerebral hemodynamics in simulated hypovolemia in healthy volunteers.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to determine the agreement between blood velocity in the medial cerebral and internal or common carotid arteries. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age > 18 years. - Age < 50 years. |
|
E.4 | Principal exclusion criteria |
1. Any medical condition limiting physical exertional capacity or requiring regular medication (allergy and contraceptives excepted). 2. Pregnancy. 3. Breastfeeding. 4. History of syncope (syncope of presumed vasovagal nature with known precipitating factor excepted). 5. Any known cardiac arrhythmia. Prior/Concomitant Therapy 6. Any drug (contraceptives excepted) used on a regular basis for a chronic condition (allergy excepted).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Determine if there is an effect of supplemental oxygen on cardiac output during LBNP.
Cardiac output will be measured continuously by volume-clamp method and suprasternal Doppler if needed (e.g. due to poor signal quality). The primary aim of the study is to test the difference of oxygen compared ro placebo. P-values <0.05 are considered statistically significant. Cardiac output will be entered as a continuous explanatory variable in a linear mixed effects regression model. Analyses will be performed by assigning variables (dummy coding) to each medication. Confidence intervals for the effect of each medication will be calculated using the glht-function of the “multcomp”-package in R with “single step” correction for multiple comparisons. No interim-analyses will be performed. Missing values will not be imputed, but are generally handled well in mixed effects regression models. The exact setup of the statistical model (e.g. random intercept vs. random slope, interaction effects, covariance structures etc.) will depend on details in the data. Analyses will be performed using the statistical software R (https://www.r-project.org/).
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Continuously during LBNP-exposure. |
|
E.5.2 | Secondary end point(s) |
• Effect of oxygen and LNBP on changes in middle cerebral artery blood flow velocity (MCAV). • Effect of oxygen and LNBP on changes in cardiac stroke volume. • Effect of oxygen and LNBP on changes time to decompensation.
- Change in MCAV with increasing LBNP will be analyzed in a linear mixed effects model corresponding to cardiac output (see above). - Change in stroke volume with increasing LBNP will be analyzed in a linear mixed effects model corresponding to cardiac output (see above). - Time to hemodynamic decompensation will be compared between the three interventions in a mixed proportional hazards model (Cox regression).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Continuously during LBNP-exposure. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |